Skip to main content
Clinical Trials/NCT02148848
NCT02148848
Unknown
Phase 4

A Comparative Study of Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty in Patients With Osteoporotic Femoral Neck Fractures

Mahidol University1 site in 1 country86 target enrollmentJune 2013

Overview

Phase
Phase 4
Intervention
Risedronate
Conditions
Osteoporotic Fractures
Sponsor
Mahidol University
Enrollment
86
Locations
1
Primary Endpoint
de Morton Mobility Index
Last Updated
9 years ago

Overview

Brief Summary

Femoral neck fracture in the elderly is one indication for initiating osteoporosis treatment. Bisphosphonates remain the first line therapy; however, many orthopaedic surgeons concern regarding their effects on fracture healing process. Therefore, therapy is usually delayed for a period of time. To the best of our knowledge, there is no scientific data to support whether bisphosphonate treatment should be given immediately after the surgery or it should be delayed.

Detailed Description

Femoral neck fracture in the elderly is one indication for initiating osteoporosis treatment. Bisphosphonates remain the first line therapy; however, many orthopaedic surgeons concern regarding their effects on fracture healing process. Therefore, therapy is usually delayed for a period of time. To the best of our knowledge, there is no scientific data to support whether bisphosphonate treatment should be given immediately after the surgery or it should be delayed. This study aims to compare functional recovery between early- and late administration of bisphosphonate in patients who received hemiarthroplasty following femoral neck fractures.

Registry
clinicaltrials.gov
Start Date
June 2013
End Date
October 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient diagnosed with femoral neck fracture and was treated with bipolar hemiarthroplasty
  • Age more than 50 years old and bone mineral density (BMD) was in osteoporotic (T-score less than -2.5) or osteopenic (T-score between -1.0 and -2.5) ranges

Exclusion Criteria

  • Patients who were treated with bipolar hemiarthroplasty for more than 2 weeks
  • Patients with postoperative complications which affect the postoperative rehabilitation program e.g. intraoperative cracking or fracture, postoperative cardiac complication
  • Have contraindications for bisphosphonates use e.g. renal insufficiency (glomerular filtration rate (GFR) \< 30 ml/min), allergy to bisphosphonates, severe esophagitis, gastroesophageal reflux disease etc.
  • Patients with conditions/disorders which have an affect on bone mineral density or bone metabolism e.g. renal insufficiency, rheumatoid arthritis, Paget's disease, renal osteodystrophy, hyperparathyroidism, glucocorticoids use etc.
  • History of bisphosphonates use within 12 months
  • Open fracture, multiple fracture or multiple trauma patients
  • Pathological fracture
  • Bilateral lower extremity fractures
  • The pre-injury functional status of the patients is non-ambulatory

Arms & Interventions

Early bisphosphonate use

Give risedronate (actonel) at 2 weeks after hemiarthroplasty for an osteoporotic femoral neck fracture. In addition, calcium and vitamin D supplementation will be given to all patients. Risedronate (35 mg) 1 tablet orally once a week

Intervention: Risedronate

Outcomes

Primary Outcomes

de Morton Mobility Index

Time Frame: 3 months after surgery

Secondary Outcomes

  • Visual analog scale score(3 months after surgery)
  • Two minutes walking test(3 months after surgery)
  • Timed get up and go test(3 months after surgery)
  • Barthel index(3 months after surgery)
  • EuroQoL-5D (EQ-5D)(3 months after surgery)

Study Sites (1)

Loading locations...

Similar Trials